Clinical and Molecular Hepatology,
Journal Year:
2023,
Volume and Issue:
29(2), P. 320 - 331
Published: Feb. 2, 2023
The
prevalence
of
metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD)
has
increased
among
the
general
population
and
chronic
hepatitis
B
(CHB)
patients
worldwide.
Although
is
a
well-known
risk
factor
for
adverse
outcomes
like
cirrhosis
hepatocellular
carcinoma,
its
interactions
with
virus
(HBV)
clinical
impacts
seem
complex.
presence
hepatic
steatosis
may
suppress
HBV
viral
activity,
potentially
leading
to
attenuated
injury.
In
contrast,
associated
co-morbidities
diabetes
mellitus
or
obesity
increase
developing
outcomes.
These
findings
implicate
that
components
MAFLD
have
diverse
effects
on
manifestations
CHB.
To
this
end,
strategy
proposed
managing
concurrent
CHB
MAFLD.
This
review
article
discusses
updated
evidence
regarding
prevalence,
between
HBV,
impacts,
management
strategies,
aiming
at
optimizing
holistic
health
care
in
population.
Clinical and Molecular Hepatology,
Journal Year:
2022,
Volume and Issue:
29(Suppl), P. S17 - S31
Published: Nov. 29, 2022
“Metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD)”
is
the
term
suggested
in
2020
to
refer
related
systemic
metabolic
dysregulation.
The
name
change
from
nonalcoholic
(NAFLD)
MAFLD
comes
with
a
simple
set
of
criteria
enable
easy
diagnosis
at
bedside
for
general
medical
community,
including
primary
care
physicians.
Since
introduction
term,
there
have
been
key
areas
which
superiority
over
traditional
NAFLD
terminology
has
demonstrated,
risk
and
extrahepatic
mortality,
associations,
identifying
high-risk
individuals.
Additionally,
adopted
by
number
leading
pan-national
national
societies
due
its
concise
diagnostic
criterion,
removal
requirement
exclude
concomitant
diseases,
reduction
stigma
associated
this
condition.
current
article
explores
differences
between
diagnosis,
benefit,
some
potential
limitations,
how
opened
up
new
fields
research.
The Journal of Clinical Endocrinology & Metabolism,
Journal Year:
2022,
Volume and Issue:
107(9), P. 2691 - 2700
Published: May 19, 2022
Abstract
Background
and
Aims
Metabolic-associated
fatty
liver
disease
(MAFLD)
was
proposed
as
a
better
definition
of
nonalcoholic
(NAFLD)
to
encompass
the
metabolic
dysregulation
associated
with
NAFLD.
This
redefinition
challenges
our
understanding
disease.
Hence,
this
study
sought
conduct
an
updated
analysis
prevalence,
clinical
characteristics,
factors
MAFLD,
further
sensitivity
done
based
on
lean
nonobese
MAFLD
individuals.
Methods
Medline
Embase
databases
were
searched
include
articles
MAFLD.
Meta-analysis
proportions
conducted
using
generalized
linear
mix
model.
Associating
evaluated
in
conventional
pairwise
meta-analysis
Results
From
pooled
involving
3
320
108
individuals,
overall
prevalence
38.77%
(95%
CI
32.94%
44.95%);
5.37%
4.36%
6.59%)
29.78%
26.06%
33.79%)
respectively,
had
Metabolic
complications
such
hypertension
[odds
ratio
(OR)
2.63,
95%
1.85
3.74,
P
<
0.0001
OR
2.03;
1.74
2.38,
0.0001,
respectively]
diabetes
(OR
3.80,
2.65
5.43,
3.46,
2.81
4.27,
respectively)
found
significant
associating
Conclusions
supports
previous
studies
reporting
affect
more
than
third
global
population.
While
exploration
pathogenic
basis
without
is
required,
emphasis
management
concomitant
can
improve
multidisciplinary
efforts
managing
complex
Liver International,
Journal Year:
2021,
Volume and Issue:
41(6), P. 1290 - 1293
Published: Feb. 16, 2021
Abstract
Data
are
limited
on
the
epidemiological
implications
of
recent
change
in
terminology
from
nonalcoholic
fatty
liver
disease
(NAFLD)
to
metabolic
dysfunction‐associated
(MAFLD).
We
therefore
performed
a
cross‐sectional
study
adults
recruited
2017‐2018
National
Health
and
Nutrition
Examination
Survey,
representative
sample
general
US
population.
The
prevalence
NAFLD
MAFLD
based
controlled
attenuation
parameter
(CAP)
stiffness
measurement
(LSM)
obtained
through
vibration‐controlled
transient
elastography
(VCTE)
were
37.1%
(95%
CI
34.0‐40.4)
39.1%
36.3‐42.1),
respectively,
with
higher
rates
among
Hispanic
individuals.
Agreement
between
two
definitions
was
high
(Cohen's
κ
0.92).
Patients
also
showed
similar
risk
advanced
fibrosis
(7.5%
7.4%
respectively).
Our
results
suggest
that
diagnostic
criteria
did
not
affect
condition
United
States
